Clinical Trials Browser

Lutetium-177 × NET × 30 days × Clear all

NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Phase 3 Recruiting

EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor